# A study on the nutritional status and body composition of children with Hutchinson–Gilford progeria syndrome

**Authors:** Qinmei Yu, Jingjing Wang, Haidong Fu, Jianhua Mao

PMC · DOI: 10.1186/s13023-025-04164-7 · 2026-01-12

## TL;DR

This study examines the growth, nutrition, and body composition of children with a rare aging disorder to guide better dietary and therapeutic strategies.

## Contribution

The study provides detailed insights into body composition and nutritional needs specific to Hutchinson-Gilford Progeria Syndrome patients.

## Key findings

- HGPS patients show severe growth retardation and reduced bone density compared to healthy controls.
- Abnormal fat distribution and reduced muscle mass were observed in HGPS patients.
- Nutrient-dense diets with increased protein and specific supplements are recommended for HGPS patients.

## Abstract

Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic disorder characterized by premature aging, severe growth retardation, and metabolic abnormalities. This study aimed to evaluate the growth, nutritional status, and body composition of HGPS patients, with a focus on fat and muscle distribution, to provide insights into potential nutritional and therapeutic interventions.

Eight HGPS patients (aged ≥ 3 years) and 18 age- and sex-matched healthy controls were enrolled. Physical assessments, dietary surveys, and laboratory tests were conducted, including dual-energy X-ray absorptiometry (DXA) to analyze bone density, fat distribution, and muscle mass. Genetic testing confirmed LMNA mutations in all patients. Data on growth parameters, dietary intake, and metabolic profiles were collected and compared with controls.

HGPS patients exhibited severe growth retardation, with significant declines in height and weight by two months of age compared to controls. Dietary surveys revealed that 4 out of 8 subjects had sufficient energy intake, the energy intake was 91 ± 39% of the estimated basal metabolic rate. DXA analysis showed reduced bone density (Z-score: -2.82 ± 1.46), abnormal fat distribution (increased visceral fat and decreased subcutaneous fat, the T/L fat ratio and A/G fat ratio > 95th percentile for boys and girls in China), and significant reductions in total and limb muscle mass(< mean-2SD).

HGPS patients experience profound growth retardation, metabolic dysfunction, and abnormal body composition, including reduced muscle mass and altered fat distribution. A nutrient-dense diet with increased protein intake, healthy fat intake, and supplementation with vitamin D, calcium, and zinc are essential to support growth and muscle maintenance. Tailored and individualised dietary interventions may further improve outcomes. Continuous monitoring and further research are needed to optimize interventions and enhance the quality of life for HGPS patients.

## Linked entities

- **Genes:** LMNA (lamin A/C) [NCBI Gene 4000]
- **Diseases:** Hutchinson-Gilford Progeria Syndrome (MONDO:0008310)

## Full-text entities

- **Genes:** GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, IGF1R (insulin like growth factor 1 receptor) [NCBI Gene 3480] {aka CD221, IGFIR, IGFR, JTK13}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, VDR (vitamin D receptor) [NCBI Gene 7421] {aka NR1I1, PPP1R163}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}, BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}, IGFBP3 (insulin like growth factor binding protein 3) [NCBI Gene 3486] {aka BP-53, IBP-3, IBP3, IGFBP-3}, LMNA (lamin A/C) [NCBI Gene 4000] {aka CDCD1, CDDC, CMD1A, CMT2B1, EMD2, FPL}
- **Diseases:** abnormal tooth development (MESH:D002658), joint deformities (MESH:D016916), ischemic necrosis (MESH:D005271), malocclusion (MESH:D008310), cardio- vascular disease (MESH:D014652), conductive hearing loss (MESH:D006314), abnormal body composition (MESH:C564221), reductions in (MESH:D015431), abdominal obesity (MESH:D056128), hip dislocation (MESH:D006617), coxa valgus deformity (MESH:D060906), hyperlipidemia (MESH:D006949), reduced bone density (MESH:D001851), stroke (MESH:D020521), vascular calcification (MESH:D061205), metabolic dysregulation (MESH:D021081), inflammatory (MESH:D007249), atherosclerosis (MESH:D050197), adiposity (MESH:D018205), osteolysis (MESH:D010014), myocardial infarction (MESH:D009203), carotid atherosclerotic plaques (MESH:D016893), reduced muscle (MESH:D009135), bone dysplasia (MESH:D001848), joint contracture (MESH:D003286), metabolic abnormalities (MESH:D008659), difficulty in mouth opening (MESH:D009059), muscle atrophy (MESH:D009133), abdominal adiposity (MESH:D000007), skeletal disorders (MESH:C564967), fat (MESH:D004620), preterm birth (MESH:D047928), fatty malnutrition (MESH:D044342), asphyxia (MESH:D001237), osteoporosis (MESH:D010024), death (MESH:D003643), atherosclerotic plaques (MESH:D058226), toxicity (MESH:D064420), Low skeletal muscle mass (MESH:C536030), hair loss (MESH:D000505), obese (MESH:D009765), skeletal dysplasia (MESH:C535858), cardiovascular and cerebrovascular diseases (MESH:D002318), growth retardation (MESH:D006130), fracture (MESH:D050723), visceral fat (MESH:D007418), genetic disorder (MESH:D030342), muscle (MESH:D019042), Insulin resistance (MESH:D007333), growth failure (MESH:D051437), vascular dysfunction (MESH:D002561), skin scleroderma (MESH:D012595), right ventricular diastolic dysfunction (MESH:D018487), cardiac disorders (MESH:D006331), biventricular dysfunction (MESH:D018754), heart failure (MESH:D006333), spinal curvature (MESH:D013121), skin hardening (MESH:D012871), joint dislocation (MESH:D004204), HGPS (MESH:D011371)
- **Chemicals:** fructose (MESH:D005632), Calcium (MESH:D002118), uric acid (MESH:D014527), glycogen (MESH:D006003), Vitamin D (MESH:D014807), H (MESH:D006859), carbohydrate (MESH:D002241), lipid (MESH:D008055), triglycerides (MESH:D014280), glucose (MESH:D005947), HDL-C (-), zinc (MESH:D015032), phosphorus (MESH:D010758), amino acids (MESH:D000596), Magnesium (MESH:D008274), W (MESH:D014414), blood sugar (MESH:D001786), cholesterol (MESH:D002784)
- **Species:** Lathyrus oleraceus (garden pea, species) [taxon 3888], Mus musculus (house mouse, species) [taxon 10090], Powellomyces sp. EA (species) [taxon 252690], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G608S, c.1968 + 5G > C, G608G, A/G

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12797671/full.md

---
Source: https://tomesphere.com/paper/PMC12797671